loading…
Q2056 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
BackQ2004Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml→Q2009Injection, fosphenytoin, 50 mg phenytoin equivalent→Q2026Injection, radiesse, 0.1 ml→Q2028Injection, sculptra, 0.5 mg→Q2034Influenza virus vaccine, split virus, for intramuscular use (agriflu)→Q2035Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)→Q2036Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)→Q2037Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)→Q2038Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)→Q2039Influenza virus vaccine, not otherwise specified→Q2041Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose→Q2042Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose→Q2043Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion→Q2049Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg→Q2050Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg→Q2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)→Q2053Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose→Q2054Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose→Q2055Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose→Q2056Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose→Q2057Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose→Q2058Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion→
Procedure codeCODABLE
Q2056
Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Part
- HCPCS Level II
- Q
- Temporary Codes
- Q2
- Q2004–Q2058
Source
CMS — ICD-10-PCS FY2026, HCPCS Level II october 2026, Procedure Codes 2026.